Clinical study on safety and efficacy of adoptive transfer of autologous gamma/delta T lymphocytes in patients with non-small cell lung cancer.

Clinical study on safety and efficacy of adoptive transfer of autologous gamma/delta T lymphocytes in patients with non-small cell lung cancer. - Clinical study of gamma/delta T cell therapy for non-small cell lung cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000336

Enrollment

Registered

2006-03-01

Start date

2006-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer

Interventions

Gamma/delta T cells are to be administrated intravenously 6 times on a biweekly-basis.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-small cell lung cancer patients -whose life-expectancy is more than 6 months; -20 years or more; -Performance status 0-1; -No serious abnormality in bone marrow, liver and/or renal functions.

Exclusion criteria

Exclusion criteria: Patients who have: -uncontrolled infections; -active autoimmune diseases; -serious cardiac disease; -other cancers; -who have received continuous systemic steroids; -who are pregnant, to be pregnant, or nursing mothers; -whom principle investigator or co-investigator judged to be inappropriate to participate in this study.

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Antitumor effect (response rate, duration of response), improvement of tumor-related maker, immunological parameter, QOL score and Progression-free survival.	—

Countries

Japan

Contacts

Public ContactKazuhiro Kakimi

University of Tokyo, Graduate School of Medicine Department of Immunotherapeutics

immunotherapy-admin@umin.ac.jp03-5805-3161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026